A Phase 2b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPI-1005 to Reduce the Incidence, Severity and Duration of Acute Noise Induced Hearing Loss (NIHL)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Ebselen (Primary)
- Indications Noise-induced hearing loss
- Focus Therapeutic Use
- Acronyms NIHL
- Sponsors Sound Pharmaceuticals
- 21 Sep 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2019.
- 21 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2019.
- 21 Sep 2017 Planned initiation date changed from 1 Sep 2016 to 1 Feb 2018.